These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 26293898)

  • 1. The anti-ovarian cancer activity by WYE-132, a mTORC1/2 dual inhibitor.
    Zhang D; Xia H; Zhang W; Fang B
    Tumour Biol; 2016 Jan; 37(1):1327-36. PubMed ID: 26293898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent inhibition of mTORC1 and mTORC2 by WYE-687 inhibits renal cell carcinoma cell growth in vitro and in vivo.
    Pan XD; Gu DH; Mao JH; Zhu H; Chen X; Zheng B; Shan Y
    PLoS One; 2017; 12(3):e0172555. PubMed ID: 28257457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autophagy inhibition sensitizes WYE-354-induced anti-colon cancer activity in vitro and in vivo.
    Wang L; Zhu YR; Wang S; Zhao S
    Tumour Biol; 2016 Sep; 37(9):11743-11752. PubMed ID: 27020593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical evaluation of WYE-687, a mTOR kinase inhibitor, as a potential anti-acute myeloid leukemia agent.
    Cheng F; Wang L; Shen Y; Xia J; Chen H; Jiang Y; Lu M
    Biochem Biophys Res Commun; 2016 Feb; 470(2):324-330. PubMed ID: 26792718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.
    Yu K; Shi C; Toral-Barza L; Lucas J; Shor B; Kim JE; Zhang WG; Mahoney R; Gaydos C; Tardio L; Kim SK; Conant R; Curran K; Kaplan J; Verheijen J; Ayral-Kaloustian S; Mansour TS; Abraham RT; Zask A; Gibbons JJ
    Cancer Res; 2010 Jan; 70(2):621-31. PubMed ID: 20068177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-clinical evaluation of AZD-2014, a novel mTORC1/2 dual inhibitor, against renal cell carcinoma.
    Zheng B; Mao JH; Qian L; Zhu H; Gu DH; Pan XD; Yi F; Ji DM
    Cancer Lett; 2015 Feb; 357(2):468-75. PubMed ID: 25444920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer.
    Hussain AR; Al-Romaizan M; Ahmed M; Thangavel S; Al-Dayel F; Beg S; Uddin S; Siraj AK; Al-Kuraya KS
    Mol Med; 2015 May; 21(1):466-78. PubMed ID: 26023849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C6 ceramide sensitizes the anti-hepatocellular carcinoma (HCC) activity by AZD-8055, a novel mTORC1/2 dual inhibitor.
    Liu M; Gu P; Guo W; Fan X
    Tumour Biol; 2016 Aug; 37(8):11039-48. PubMed ID: 26897748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual targeting of mTORC1 and mTORC2 by INK-128 potently inhibits human prostate cancer cell growth in vitro and in vivo.
    Jiang SJ; Wang S
    Tumour Biol; 2015 Sep; 36(10):8177-84. PubMed ID: 25990456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dramatic suppression of colorectal cancer cell growth by the dual mTORC1 and mTORC2 inhibitor AZD-2014.
    Huo HZ; Zhou ZY; Wang B; Qin J; Liu WY; Gu Y
    Biochem Biophys Res Commun; 2014 Jan; 443(2):406-12. PubMed ID: 24309100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin.
    Yu K; Toral-Barza L; Shi C; Zhang WG; Lucas J; Shor B; Kim J; Verheijen J; Curran K; Malwitz DJ; Cole DC; Ellingboe J; Ayral-Kaloustian S; Mansour TS; Gibbons JJ; Abraham RT; Nowak P; Zask A
    Cancer Res; 2009 Aug; 69(15):6232-40. PubMed ID: 19584280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The anti-tumor activator sMEK1 and paclitaxel additively decrease expression of HIF-1α and VEGF via mTORC1-S6K/4E-BP-dependent signaling pathways.
    Kim BR; Yoon K; Byun HJ; Seo SH; Lee SH; Rho SB
    Oncotarget; 2014 Aug; 5(15):6540-51. PubMed ID: 25153728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting sphingosine kinase 1/2 by a novel dual inhibitor SKI-349 suppresses non-small cell lung cancer cell growth.
    Xue Y; Jiang K; Ou L; Shen M; Yang Y; Lu J; Xu W
    Cell Death Dis; 2022 Jul; 13(7):602. PubMed ID: 35831279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
    Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
    Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AT7867 Inhibits Human Colorectal Cancer Cells via AKT-Dependent and AKT-Independent Mechanisms.
    Zhang S; Deng Z; Yao C; Huang P; Zhang Y; Cao S; Li X
    PLoS One; 2017; 12(1):e0169585. PubMed ID: 28081222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma.
    Ahmed M; Hussain AR; Bavi P; Ahmed SO; Al Sobhi SS; Al-Dayel F; Uddin S; Al-Kuraya KS
    Carcinogenesis; 2014 Jul; 35(7):1564-72. PubMed ID: 24583924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic co-inhibition of Mnks and mTORC1 synergistically suppresses proliferation and perturbs cell cycle progression in blast crisis-chronic myeloid leukemia cells.
    Teo T; Yu M; Yang Y; Gillam T; Lam F; Sykes MJ; Wang S
    Cancer Lett; 2015 Feb; 357(2):612-23. PubMed ID: 25527453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTORC1 is a target of nordihydroguaiaretic acid to prevent breast tumor growth in vitro and in vivo.
    Zhang Y; Xu S; Lin J; Yao G; Han Z; Liang B; Zou Z; Chen Z; Song Q; Dai Y; Gao T; Liu A; Bai X
    Breast Cancer Res Treat; 2012 Nov; 136(2):379-88. PubMed ID: 23053656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The anti-esophageal cancer cell activity by a novel tyrosine/phosphoinositide kinase inhibitor PP121.
    Peng Y; Zhou Y; Cheng L; Hu D; Zhou X; Wang Z; Xie C; Zhou F
    Biochem Biophys Res Commun; 2015 Sep; 465(1):137-44. PubMed ID: 26235881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-level suppression of receptor-PI3K-mTORC1 by fatty acid synthase inhibitors is crucial for their efficacy against ovarian cancer cells.
    Wagner R; Stübiger G; Veigel D; Wuczkowski M; Lanzerstorfer P; Weghuber J; Karteris E; Nowikovsky K; Wilfinger-Lutz N; Singer CF; Colomer R; Benhamú B; López-Rodríguez ML; Valent P; Grunt TW
    Oncotarget; 2017 Feb; 8(7):11600-11613. PubMed ID: 28086243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.